Print Friendly, PDF & Email

Pantana & Lutzker Close $5.25 Million Direct Offering

August 21, 2023 – Federica Pantana, Associate and Elliot Lutzker, Partner and Chair of the Corporate & Securities Law practice represented Cosmos Health, providing advice and counsel on all phases of the offering, from deal negotiation to drafting and/or reviewing of the stock purchase agreement, placement agency agreement, warrants, registration statement/prospectus along with ancillary documents, handled filings and communications with the SEC and Nasdaq, coordinated and supervised deal pricing and closing.

Cosmos Health Inc. (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced the successful closing of a $5.25 Million Registered Direct Offering and Concurrent Private Placement.

The offering, which closed on July 21, 2023, consisted of 2,116,936 shares of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and common warrants to purchase up to 1,935,484 shares of common stock in a concurrent private placement (together with the registered direct offering, the “offering”). The combined purchase price for one share of common stock (or common stock equivalent) and one common warrant was $2.48 for gross proceeds of $5.25 million. The warrants have an exercise price of $2.75 per share, will be exercisable on the six-month anniversary of the issuance date, and expire five and one-half years from the issuance date. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.

Cosmos Health Inc. (Nasdaq:COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America.

View it on Yahoo Finance, click here.

Stay up to date

Subscribe to receive the latest insights and news from DHC.